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Evaluation of cortisol precursors for the diagnosis of
pituitary-dependent hypercortisolism in dogs
Abstract
The serum concentrations of cortisol, 17alpha-hydroxypregnenolone, 17alpha-hydroxyprogesterone,
21-deoxycortisol and 11-deoxycortisol were measured in 19 healthy dogs, 15 dogs with
pituitary-dependent hypercortisolism (pdh) and eight dogs with other diseases before and one hour after
an injection of synthetic adrenocorticotrophic hormone (acth). At both times the dogs with pdh had
significantly higher concentrations of cortisol, 17alpha-hydroxypregnenolone,
17alpha-hydroxyprogesterone and 21-deoxycortisol than the healthy dogs. Basal 11-deoxycortisol
concentrations were also significantly higher in dogs with pdh compared with healthy dogs. When
compared with the dogs with other diseases, the dogs with pdh had significantly higher basal and
post-acth cortisol and basal 21-deoxycortisol, and significantly lower post-acth 11-deoxycortisol
concentrations. The dogs with other diseases had significantly higher post-acth cortisol,
17alpha-hydroxyprogesterone and 11-deoxycortisol concentrations than the healthy dogs. In general, the
post-acth concentrations of 17alpha-hydroxypregnenolone, 17alpha-hydroxyprogesterone,
11-deoxycortisol and 21-deoxycortisol were more variable than the post-acth concentrations of cortisol,
resulting in large overlaps of the concentrations of these hormones between the three groups. A
two-graph receiver operating characteristic (ROC) analysis was used to maximise the sensitivity and
specificity of each hormone for diagnosing hypercortisolism; it showed that the post-acth concentration
of cortisol had the highest sensitivity and specificity. The overlaps between the healthy dogs, the dogs
with pdh and the dogs with other diseases suggested that the individual precursor hormones would not
be useful as a screening test for hypercortisolism.
Evaluation of different cortisol precursors for the diagnosis of 
pituitary-dependent hypercortisolism in dogs 
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Cortisol, 17α-OH-pregnenolone, 17α-OH-progesterone, 21-deoxycortisol and 11-
deoxycortisol were evaluated in 19 healthy dogs, 8 dogs with other diseases and 15 dogs with 
pituitary-dependent hypercortisolism (PDH) before and one hour after injection of synthetic 
adrenocorticotrophic hormone (ACTH). 
Dogs with PDH had significantly higher basal and post-ACTH cortisol, 17α-OH-
pregnenolone, 17α-OH-progesterone, 21-deoxycortisol and basal 11-deoxycotisol 
concentrations than healthy dogs. When compared to dogs with other diseases those with 
PDH had significantly higher basal and post-ACTH cortisol, basal 21-deoxycortisol and 
significantly lower post-ACTH 11-deoxycortisol levels. Dogs with other diseases had 
significantly higher post-ACTH cortisol, 17α-OH-progesterone and 11-deoxycortisol 
concentrations compared to healthy dogs. In general, post-ACTH 17α-OH-pregnenolone, 
17α-OH-progesterone, 11-deoxycortisol and 21-deoxycortisol concentrations varied more 
than post-ACTH cortisol concentrations did, resulting in a large overlap of these hormone 
values between the three groups. Maximising sensitivity and specificity of each hormone 
using a two-graph ROC analysis, revealed the highest sensitivity and specificity for post-
ACTH cortisol. 
In conclusion, 17α-OH-pregnenolone, 17α-OH-progesterone, 21-deoxycortisol and 11-
deoxycotisol concentrations were significantly elevated in dogs with PDH compared to 
healthy dogs. However, there was overlap of these hormones between healthy dogs, dogs with 
other diseases and dogs with PDH suggesting that the individual precursor hormones are not 
useful as a screening test for hypercortisolism. 
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Hypercortisolism (HC) is a frequent endocrine disease in dogs. Clinical signs are typically 
caused by excessive cortisol production, secondary either to an ACTH secreting pituitary 
tumor (pituitary-dependent HC, PDH) causing bilateral adrenocortical hyperplasia or to an 
adrenocortical adenoma or carcinoma (adrenal-dependent HC, ADH). Confirmation of HC in 
human and veterinary medicine involves demonstrating cortisol hypersecretion by measuring 
cortisol metabolites in the urine (e.g. urine corticoid-to-urine creatinine ratio) and 
demonstrating resistance to the normal suppressive effects of glucocorticoids (e.g. low dose 
dexamethason suppression test (LDDS test)). Stimulation testing (e.g. ACTH stimulation test) 
is not recommended to confirm HC in humans because it is less reliable and because there is 
considerable overlap between patients with and without HC (Nichols and others 1968, 
Hashimoto 1975). In spite of the poor results with humans, the ACTH stimulation test 
remains more popular in the veterinary field and the reported sensitivities vary between those 
in humans and those achieved with the low dose dexamethason suppression test (Kaplan and 
others 1995, Van Liew and others 1997). In recent years, investigation of other hormones, in 
particular the cortisol precursor 17α-OH-progesterone, was initiated, hoping to improve the 
diagnostic value of the ACTH stimulation test (Frank and others 2001, Ristic and others 2002, 
Chapman and others 2003, Benitah and others 2005, Hill and others 2005). In dogs with 
confirmed HC (positive screening tests), however, measuring post-ACTH 17α-OH-
progesterone concentrations had no benefit over measuring post-ACTH cortisol 
concentrations (Chapman and others 2003, Benitah and others 2005).  In contrast, in dogs with 
typical clinical signs of HC but negative ACTH stimulation and LDDS tests, evaluation of 
17α-OH-progesterone levels seemed to be of some value (Ristic and others 2002, Benitah and 
others 2005). It seems feasible that other cortisol precursors, like 17α-OH-pregnenolone, 11-
deoxycortisol or 21-deoxycortisol, could turn out to be more useful than 17α-OH-
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progesterone concentrations to diagnose HC. In a previous article the authors described these 
cortisol precursors in dogs with PDH during trilostane therapy (Sieber-Ruckstuhl and others 
2006).  
The objective of this follow-on study was to evaluate the usefulness of cortisol, 17α-OH-
pregnenolone, 17α-OH-progesterone, 11-deoxycortisol and 21-deoxycortisol in the diagnosis 
of HC by measuring these hormones in healthy dogs, in dogs with other diseases and in dogs 
with PDH. 
 
Material and methods 
Dogs and inclusion criteria 
Nineteen clinically healthy dogs, nine females (4 spayed) and 10 males (5 neutered), aged 
between 4.5 and 14 years (median, 8 years) with a bodyweight between 7.8 and 30.5 kg 
(median, 24.4 kg) were included in the study. Breeds represented included Labrador Retriever 
(n = 4), German Shepherd Dog (2), Dachshund (1), Jack Russell Terrier (1), Hovawart (1), 
Golden Retriever (1), English Cocker Spaniel (1), Beagle (1), Siberian Husky (1), German 
Shorthaired Pointer (1), and 5 mixed-breed dogs. The dogs were considered healthy on the 
basis of medical history, results of physical examination and laboratory analyses 
(haematology and biochemical profile). They were owned by students or employees of the 
Vetsuisse Faculty University of Zurich, Switzerland. Informed consent was obtained from 
owners of all dogs and their use was approved by the Swiss Cantonal Veterinary Office.   
Additionally, eight dogs with an initial clinical suspicion of HC but in which a diagnosis other 
than HC was reached were included in the study. Six were spayed females, two were neutered 
males, their age ranged between 9 and 14 years (median, 12 years) and their bodyweight 
between 7.0 and 34.2 kg (median, 8.8 kg). Breeds represented included West Highland White 
Terrier (3), Yorkshire Terrier (1), Manchester Terrier (1), Poodle (1), Golden Retriever (1), 
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and Bearded Collie (1). In all dogs a complete haematological and biochemical evaluation, a 
LDDS test, and an adrenal ultrasound were performed. Inclusion criteria were an adequate 
suppression during the LDDS test (8 hour cortisol ≤ 5.5 nmol/l) and reaching another 
diagnosis other than HC, which was either treated successfully or confirmed by post mortem 
examination. The final diagnoses achieved in these dogs were: diabetes mellitus (3), atopic 
dermatitis (1), pheochromocytoma (1), hepatic neoplastic disease (1), acute lymphatic 
leukaemia (1) and pulmonary fibrosis (1). Informed consent was obtained from the owners of 
all dogs. 
Finally fifteen dogs with HC were included in the study. Five were females (3 spayed), ten 
were males (3 neutered), age ranged between 7 and 14 years (median, 11 years) and 
bodyweight between 3.7 and 33.2 kg (median, 10.9 kg). Breeds represented included 
Dachshund (n = 4), Poodle (2), Maltese (1), Silky Terrier (1), Shih-Tzu (1), Coton de Tuléar 
(1), Lakeland Terrier (1), English Bulldog (1), Golden Retriever (1), and two mixed-breed 
dogs. In all dogs a complete haematological and biochemical evaluation, a LDDS test, 
measurement of endogenous ACTH and ultrasonographic examination of the adrenal glands 
were performed. In five dogs the urine cortisol-to-urine creatinine ratio was additionally 
evaluated twice. Dogs were included in the study when consistent clinical and laboratory 
findings for HC were detected, at least 1 screening test yielded positive results, treatment with 
trilostane showed an adequate response and the dog had not received other treatments (eg 
radiation therapy, mitotane therapy) for HC. PDH was diagnosed on the basis of the 
concentration of endogenous ACTH and a symmetrical appearance, with or without 
enlargement of the adrenal glands during ultrasonographic examination. Informed consent 
was obtained from the owners of all dogs. In more detail, 13 dogs had an 8-hour cortisol value 
of > 27.6 nmol/l, one dog had an inverse test result (0-hour cortisol 96.6 nmol/l, 4-hour 
cortisol 19.3 nmol/l, 8-hour cortisol 13.8 nmol/l) and one had a normal LDDS rest result 
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although no complete suppression (0-hour cortisol 113.1 nmol/l, 4- and 8-hour cortisol 11 
nmol/l) (Mueller and others 2006). The two dogs with the inverse or the normal LDDS test 
had both two positive urine cortisol-to-urine creatinine ratios. All dogs responded favourably 
to trilostane treatment. 
Endocrinologic analyses 
The ACTH stimulation test was performed by collecting blood samples for determination of 
serum concentrations of cortisol, 17α-OH-pregnenolone, 17-OH-progesterone, 11-
deoxycortisol and 21-deoxycortisol before and 1 hour after IM injection of 0.25 mg of 
synthetic ACTH (Synacthen®; Novartis Pharma Schweiz AG). The serum was separated and 
stored at -80º until assayed. Cortisol concentrations were determined by use of 
chemiluminescence assay (ADVIA Centaur® System; Bayer AG) as reported previously 
(Ruckstuhl and others 2002, Wenger and others 2004). 17α-OH-pregnenolone, 17α-OH-
progesterone, 11-deoxycortisol, and 21-deoxycortisol were measured by specific in-house 
radioimmunoassay (RIA) established at the Steroid Laboratory of the University of 
Heidelberg, Germany, using titrated steroids (Amersham Bioscience) as reported previously 
(Sieber-Ruckstuhl and others 2006). Antibodies were raised and characterized in the steroid 
laboratory, as described elsewhere (Vecsei and others 1972,Vecsei 1978, Vecsei 1979). 
Before RIA a recovery-corrected extraction was performed for all hormones and 
chromatographic purification was performed for 17-OH-progesterone and 21-deoxycortisol to 
remove cross-reacting steroids. The chromatographic separation on microcolumns modified 
from the method previously described was carried out using Celite (Celite 545 AW; Sigma 
Aldrich) as an inert support for partition chromatography (Abraham and others 1972). 
Standard curves of all steroids measured ranged from 2pg/tube to 1000 pg/tube and 
sensitivities were 0.2 nmol/, 0.4 nmol/l, 0.1 nmol/l and 0.6 nmol/l for 17α-OH-pregnenolone, 
17α-OH-progesterone, 21-deoxycortisol and 11-deoxycortisol, respectively. Intra- and inter-
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assay coefficients of variation were 6.2 % and 13 %, 8.6 % and 11.3 %, 7 % and 12.6 % and 
8.2 % and 11.6 % for 17α-OH-pregnenolone, 17α-OH-progesterone, 11-deoxycortisol and 
21-deoxycortisol, respectively.  
In dogs with HC the low dose dexamethasone suppression test and the urine cortisol-to- 
creatinine ratio were performed as reported previously (Ruckstuhl and others 2002, Wenger 
and others 2004).  
 
Statistical analysis 
Results were analyzed by use of nonparametric statistical methods (SPSS 11.0 for Windows, 
SPSS Inc; GraphPad Prism 4;GraphPad Software Inc). Ranges and median values are 
reported. Differences between the groups were tested by use of the Mann-Whitney-U-test. 
Linear correlation was calculated by Spearman nonparametric correlation. Differences were 
considered significant at values of p ≤ 0.05. Receiver operating curves (ROCs) were derived 
for each hormone and the area under the curve (AUC) was calculated for all of them. For 
values below the detection limit the mean between 0 and the detection limit was entered for 
statistical analysis. 
 
Results 
Cortisol precursor and cortisol concentrations (Table 1 and figure 1-3) 
Dogs with PDH had significantly higher basal and post-ACTH cortisol, 17α-OH-
pregnenolone, 17α-OH-progesterone, 21-deoxycortisol and basal 11-deoxycortisol 
concentrations compared to healthy dogs. Compared to dogs with other diseases, dogs with 
PDH had significantly higher basal and post-ACTH cortisol and basal 21-deoxycortisol 
concentrations and significantly lower post-ACTH 11-deoxycortisol concentrations. 
Dogs with other diseases had significantly higher post-ACTH cortisol, post-ACTH  
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17α-OH-progesterone and post-ACTH 11-deoxycortisol concentrations than healthy dogs. 
Correlation of cortisol precursors and cortisol  
There was a positive correlation between basal and post-ACTH 17α-OH-pregnenolone, 17α-
OH-progesterone, 21-deoxycortisol, 11-deoxycortisol levels and the corresponding cortisol 
concentration (p= 0.01 and 0.02; 0.004 and <0.0001; 0.008 and <0.0001; 0.0004 and 0.009) in 
all dogs. The spearman correlation coefficient for cortisol to basal and post-ACTH 17α-OH-
pregnenolone, 17α-OH-progesterone, 21-deoxycortisol and 11-deoxycortisol concentrations 
were 0.4 and 0.4; 0.5 and 0.7; 0.4 and 0.6; 0.5 and 0.4, respectively. 
 
ROC analysis (Table 2 and 3 and figure 4) 
The AUC of the ROC was highest for post-ACTH cortisol, followed by basal cortisol, basal 
17α-OH-pregnenolone, post-ACTH progesterone, basal 17α-OH-progesterone, post-ACTH 
21-deoxycortisol, post ACTH 17α-OH-pregnenolone, basal 21-deoxycortisol, basal 11-
deoxycortisol, post-ACTH 11-deoxycortisol (Fig. 4). The exact values for the AUC and the 
95 % confidence interval are presented in table 2.  
Maximising both, the sensitivity and the specificity of all post-ACTH hormones revealed a 
cut-off value of 570 nmol/l, 6.6 nmol/l, 6.2 nmol/l, 2.1 pmol/l and 41.9 nmol/l, for post-
ACTH cortisol, 17α-OH-pregnenolone, 17α-OH-progesterone, 21-deoxycortisol and 11-
deoxycortisol, respectively. With these cut-off values 14/15 dogs with PDH had an elevated 
cortisol, 8/14 an elevated 17α-OH-pregnenolone, 9/14 an elevated 17α-OH-progesterone, 
9/14 an elevated 21-deoxycortisol and 6/12 and elevated 11-deoxycortisol concentration. The 
one dog with the normal post-ACTH cortisol concentration had a clearly positive LDDS test 
result (0-hour cortisol 74.5 nmol/l, 4-hours cortisol 8.3 nmol/l, 8-hours cortisol 129.7 nmol/l).  
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Of the dogs with other diseases 1/8 had an elevated cortisol, 3/8 an elevated 17α-OH-
pregnenolone, 7/8 an elevated 17α-OH-progesterone, 4/7 an elevated 21-deoxycortisol and 
7/8 an elevated 11-deoxycortisol concentration with the above mentioned cut-off values.  
The cut-off values and the maximal sensitivity and specificity for each post-ACTH hormone 
are presented in table 3. 
 
Discussion 
Dogs with PDH had significantly elevated 17α-OH-pregnenolone, 17α-OH-progesterone, 21-
deoxycortisol and 11-deoxycortisol concentrations compared to healthy dogs. 
Elevated 17α-OH-progesterone values in dogs with PDH have been described in several 
studies (Frank and others 2001, Ristic and others 2002, Chapman and others 2003, Hill and 
others 2005, Benitah and others 2005), none however, has looked at 17α-OH-pregnenolone, 
11-deoxycortisol or 21-deoxycortisol concentrations. The rate-limiting step of the cortisol 
synthesis and the major site of ACTH action is the conversion of cholesterol to pregnenolone 
(Melmed and Kleinberg 2003). It is therefore not surprising that any disease causing increased 
ACTH concentrations leads, in addition to increased cortisol values, to elevated cortisol 
precursor concentrations. Measurement of 17α-OH-pregnenolone, 17α-OH-progesterone, 21-
deoxycortisol and 11-deoxycortisol seems, however, unlikely to be more advantageous for 
diagnosing PDH than measurement of cortisol. First, because the correlations between 
cortisol precursors and cortisol concentrations were rather low. Second, because post-ACTH 
17α-OH-pregnenolone, 17α-OH-progesterone, 21-deoxycortisol and 11-deoxycortisol levels 
of all three groups varied more than post-ACTH cortisol concentrations, resulting in a larger 
overlap of hormone levels between healthy dogs, dogs with other diseases and dogs with 
PDH. Finally, because the AUC of the ROC was highest for post-ACTH cortisol (0.98) 
followed by basal cortisol (0.93). The AUC under a ROC curve quantifies the overall ability 
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of the test to discriminate between those individuals with the disease and those without the 
disease. A perfect test (no false positive or negative results) has an AUC of 1.0, a useless test 
one of 0.5. The cortisol precursors in the present study had an AUC between 0.51-0.83.  
A previous study evaluating basal and post-ACTH 17α-OH-progesterone concentrations for 
the diagnosis of HC in dogs presented similar results (Chapman and others 2003). Because of 
the overlap in test results between healthy dogs and dogs with HC and between dogs with 
other diseases and dogs with HC, assessing 17α-OH-progesterone was considered 
significantly less accurate than assessing cortisol for diagnosing HC. The AUC for post-
ACTH cortisol, basal cortisol, post-ACTH 17α-OH-progesterone and basal 17α-OH-
progesterone were 0.94, 0.84, 0.76 and 0.74, which compares well to results from the present 
study (Chapman and others 2003).   
Despite the discussion above, one should remember that in human medicine the ACTH 
stimulation test is not considered a screening test for HC due to its poor sensitivity (Nichols 
and others 1968, Hashimoto 1975). An accepted gold standard method for diagnosing HC 
does not exist. To confirm the suspicion of glucocorticoid excess in humans the measurement 
of urinary free cortisol and the low-dose or the overnight dexamethasone suppression test are 
mainly used (Stewart 2003). In veterinary medicine the use of the ACTH stimulation test as a 
screening test for HC has also become a topic of critical discussions. Diagnosing HC in dogs 
usually demands the combination of typical clinical signs, laboratory alterations, abnormal 
screening tests, exclusion of other diseases and a favourable response to trilostane or mitotane 
treatment. Due to the lack of a gold standard method to diagnose HC inclusion criteria are 
often a source of criticism. All dogs with HC of the present study fulfilled the above-
mentioned points. During the LDDS test, thirteen dogs showed an 8-hour cortisol 
concentration of > 27.6 nmol/l, one dog showed the recently described inverse pattern and one 
dog showed suppression (Mueller and others 2006). The two dogs with the 8-hour cortisol 
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value < 27.6 nmol/l had elevated urine cortisol-to-urine creatinine ratios on two occasions. 
Because of increased cortisol excretion in the urine, typical clinical and laboratory signs and 
favourable response to trilostane treatment, the authors are convinced that both dogs suffered 
from HC. For comparison, a group of dogs with initial suspicion of HC, but with an adequate 
suppression during the LDDS test and in which a diagnosis other than HC was reached, were 
also studied. That dogs with occult HC would have been included seems unlikely due to the 
high sensitivity of the LDDS test (Kaplan and others 1995, Zerbe 2000). Additionally, it 
would have been ideal to include dogs with suspected HC but in which a definitive diagnosis 
could not be made by currently recommended tests. Unfortunately, only one dog with this 
pattern was available during the study period. 
In this study 14/15 dogs with PDH but only 1/8 dogs with other diseases had an abnormal 
cortisol response in the ACTH stimulation test. This calculates into a sensitivity of 93 % and a 
specificity of 88 %. These values are similar to results of a study of Van Liew and others 
(1997), which reported a sensitivity of 95 % and a specificity of 91 % for cortisol. Kaplan and 
others (1995), however, reported a clearly lower sensitivities of 80 % and a similar specificity 
of 86 %. Possible causes for the high sensitivity of cortisol in this study are the inclusion of 
only dogs with PDH and none with adrenal adenoma or carcinoma, the very strict clinical 
inclusion criteria and the small case number. The sensitivities and specificities of the 
precursor hormones in this study were lower than the ones reported for cortisol in this or in 
previous studies.  
In humans, measurement of cortisol precursors is especially indicated in adrenal-dependent 
disease. Elevated plasma pregnenolone or 17α-OH-pregnenolone concentrations in patients 
with HC indicate adrenal carcinoma, although a normal value does not exclude its presence 
(McKenna and others 1977, Orth and Kovacs 1998). In veterinary medicine, dogs with HC 
due to adrenal carcinoma were shown to secrete higher concentrations of 17α-OH-
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progesterone compared to healthy dogs, dogs with PDH and dogs with noncortisol-secreting 
adrenal tumor (Norman and others 1999, Hill and others 2005). However, because of the wide 
inter-dog variability and overlap of the hormone levels among the different types of HC, 
measurement of 17α-OH-progesterone seemed unlikely to be clinically useful (Hill and others 
2005). Other cortisol precursors, like pregnenolone, 17α-OH-pregnenolone or 11-
deoxycortisol have not yet been evaluated and studies are underway to asses if measurement 
of these cortisol precursors will be helpful to differentiate between adrenal adenoma or 
adrenal carcinoma.  
It is not known, if the elevated cortisol precursor concentrations contribute to the clinical 
signs of HC. In a previous study it was demonstrated that baseline and post-stimulation 17α-
OH-pregnenolone and baseline 11-deoxycortisol concentrations increase significantly, post-
stimulation 21-deoxycortisol concentrations decrease significantly and 17α-OH-progesterone 
concentrations do not change during trilostane therapy (Sieber-Ruckstuhl and others 2006). 
Treatment control was achieved by suppressing post-stimulation cortisol into a well-defined 
range, whereby the cortisol concentrations were highly correlated with the treatment results 
(Ruckstuhl and others 2002, Wenger and others 2004). Due to this high correlation and the 
lacking decrease in 17α-OH-pregnenolone, 11-deoxycortisol and 17α-OH-progesterone 
levels during treatment, their involvement in generating the clinical signs of HC seems rather 
unlikely. Post-stimulation 21-deoxycortisol concentrations were the only hormone levels 
(except cortisol and aldosterone concentrations), which decreased during trilostane treatment 
enabling their contribution to the clinical signs (Sieber-Ruckstuhl and others 2006). In 
humans, however, elevated 21-deoxycortisol concentrations are often seen with adrenal 
incidentalomas (Sadoul and others 1999). The fact that these patients are asymptomatic 
presumes that these hormone alterations alone do not cause major clinical signs, at least in 
humans (Sadoul and others 1999). 
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17α -OH-progesterone concentrations in the present study were lower than values reported by 
others (Chapman and others 2003, Benitah and others 2005). Different to previous 
investigators, a purification step (chromatography) preceded the measurement of 17α-OH-
progesterone by radioimmunoassays (RIA). The purpose of this purification was to decrease 
cross-reactivity, which is one of the most commonly encountered problems with RIAs. The 
distinct results of the present study most likely arise from this difference in methodology. 
In conclusion, dogs with PDH have significantly higher basal and post-ACTH cortisol, 17α-
OH-pregnenolone, 17α-OH-progesterone, 21-deoxycortisol and basal 11-deoxycortisol 
concentrations and dogs with other disease have significantly higher post-ACTH cortisol, 
post-ACTH 17α-OH-progesterone and post-ACTH 11-deoxycortisol concentrations 
compared to healthy dogs. However, in all three groups, post-ACTH 17α-OH-pregnenolone, 
17α-OH-progesterone, 11-deoxycortisol and 21-deoxycortisol concentrations varied more 
than post-ACTH cortisol concentrations, resulting in a large overlap of the hormone values 
between healthy dogs, dogs with other diseases and dogs with PDH. Therefore measurement 
of cortisol precursors cannot be recommended as a screening test for HC. 
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Figure 1 
Point plots of basal (0) and post-ACTH (1) cortisol concentrations of healthy dogs, dogs with 
other diseases and dogs with PDH.             Indicates significant difference between groups (p 
≤ 0.05). 
*
 
Figure 2 
Point plots of basal (0) and post-ACTH (1) 17α-OH-pregnenolone and 17α-OH-progesterone 
concentrations of healthy dogs, dogs with other diseases and dogs with PDH. See figure 1 for 
explanations. 
 
Figure 3 
Point plots of basal (0) and post-ACTH (1) 21-deoxycortisol and 11-deoxycorisol 
concentrations of healthy dogs, dogs with other diseases and dogs with PDH. See figure 1 for 
explanations. 
 
Figure 4 
Receiver-operator curves of post-ACTH cortisol, 17α-OH-pregnenolone, 17α-OH-
progesterone, 21-deoxycortisol and 11-deoxycorisol concentrations.  
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Table 1 402 
403 
404 
Median (range) of cortisol and cortisol precursor concentrations before and after ACTH 
stimulation of healthy dogs, dogs with other diseases and dogs with PDH. 
 Healthy dogs  Dogs with other 
diseases 
Dogs with PDH  
Hormones 0h 1h 0h 1h 0h 1h 
Cortisol  
(nmol/l) 
19.3 
(5.5-96.6) 
190 
(141-248) 
44.4 
(11.0-190) 
315 
(237-643) 
135  
(41.4-260) 
844  
(293-1291) 
17α-OH-
pregnenolone  
(nmol/l) 
1.8 
(<0.2-4.6) 
4.3 
(<0.2-10.1)
2.0 
(<0.2-7.0) 
6.0 
(0.6-23.3) 
5.5   
(<0.2-15.7) 
10.1  
(2.8-31.0) 
17α-OH-
progesterone  
(nmol/l) 
0.9 
(0.6-4.5) 
2.4 
(<0.4-9.4) 
1.0 
(0.7-2.3) 
7.9 
(3.2-13.3) 
2.4  
(0.6-19.4) 
8.2  
(2.1-18.5) 
21-
deoxycortisol  
(pmol/l) 
<0.1 
(<0.1-1.2) 
1.4 
(0.5-6.7) 
<0.1 
(<0.1) 
2.8 
(0.8-4.7) 
0.4  
(<0.1-9.6) 
4.1  
(0.4-19.8) 
11-
deoxycortisol  
(nmol/l) 
2.9 
(0.6-8.7) 
28.6 
(5.8-80.8) 
5.9 
(1.2-30.9) 
174 
(23-239) 
7.2  
(1.2-20.2) 
49.1 
(5.8-191) 
 405 
406 
407 
408 
409 
 
Table 2 
AUC and 95 % confidence interval of the hormone concentrations in declining order. 
 
Hormones AUC 95 % confidence interval 
Post-ACTH cortisol 0.98 0.95-1.0 
Basal cortisol 0.93 0.85-1.0 
Basal 17α-OH-pregnenolone 0.83 0.67-0.98 
Post-ACTH 17α-OH-progesterone 0.79 0.65-0.93 
Basal 17α-OH-progesterone 0.79 0.61-0.97 
Post-ACTH 21-deoxycortisol 0.75 0.57-0.93 
Post-ACTH 17α-OH-pregnenolone 0.70 0.52-0.88 
Basal 21-deoxycortisol 0.69 0.47-0.91 
Basal 11-deoxycortisol 0.66 0.48-0.84 
Post-ACTH 11-deoxycortisol 0.51 0.31-0.71 
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Table 3: 410 
411 
412 
Cut-off value and maximised sensitivity and specificity of all post-ACTH hormones using the 
two-graph ROC analysis. 
Hormone Cut-off value Sensitivity Specificity 
Post-ACTH cortisol  570 nmol/l 93 % 88 % 
Post-ACTH 17α-OH-pregnenolone 6.6 nmol/l 57 % 63 % 
Post-ACTH 17α-OH-progesterone 6.2 nmol/l 64 % 12.5 % 
Post-ACTH 21-deoxycortisol 2.1 pmol/l 64 % 43 % 
Post-ACTH 11-deoxycortisol 41.9 nmol/l 50 % 12.5 % 
413 
414 
415 
416 
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Figure 2 (N. Sieber-Ruckstuhl) 436 
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Figure 3 (N. Sieber-Ruckstuhl) 461 
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Figure 4 (N. Sieber-Ruckstuhl) 486 
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